{"product_id":"amphastar-marketing-mix","title":"Amphastar Pharmaceuticals Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAmphastar Pharmaceuticals leverages targeted product offerings, competitive pricing for specialty injectables, focused distribution through hospitals and specialty pharmacies, and regulatory-compliant promotional tactics to sustain market share; the preview highlights strategic strengths and execution gaps. Get the full 4Ps Marketing Mix Analysis—editable, presentation-ready, and packed with data-driven recommendations to save time and power strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary Inhalation Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar’s proprietary inhalation portfolio centers on Primatene Mist, the only FDA-approved OTC supplemental inhaler for temporary mild asthma relief, driving a dominant OTC share estimated at ~65% in 2025; unit sales grew ~8% YoY to about $145 million revenue in 2024. By end-2025 the unique HFA delivery system continues to pull share from prescription alternatives, and ongoing R\u0026amp;D targets chronic respiratory candidates using the same proprietary tech, with three programs in preclinical or Phase 1 stages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCritical Care Injectable Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar Pharmaceuticals supplies critical-care injectables like glucagon, epinephrine, and naloxone used by hospitals and EMS; these products drove 2024 injectable segment revenues of roughly $220M within Amphastar’s $430M total revenue, highlighting clinical demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Generic Medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmphastar’s specialty generics line—including enoxaparin sodium and medroxyprogesterone acetate—offers lower-cost alternatives to branded anticoagulant and hormonal therapies, with U.S. generic market prices often 30–60% below branded equivalents as of 2025.\u003c\/p\u003e\n\u003cp\u003eThese products target anticoagulation and women’s health and need sterile injectable and controlled-release manufacturing, raising COGS and regulatory spend but enabling higher gross margins than simple oral generics.\u003c\/p\u003e\n\u003cp\u003eAmphastar’s robust pipeline delivered 3 new FDA-approved generics in 2024–2025, helping offset lifecycle declines; steady launches aim to sustain revenue growth amid patent expiries and pricing pressure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsulin and Biosimilar Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmphastar advanced its insulin pipeline through late 2025, developing recombinant human insulin and insulin aspart to target the global diabetes market; clinical and CMC work aims to support high-volume biosimilar launches in 2026–2027.\u003c\/p\u003e\n\u003cp\u003eThe strategy shifts Amphastar toward vertically integrated manufacturing—API to finished dose—reducing COGS and enabling lower list prices amid complex FDA and EMA biosimilar pathways; estimated addressable market \u0026gt;US$60bn by 2030.\u003c\/p\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\n\u003cli\u003ePipeline: recombinant human insulin, insulin aspart\u003c\/li\u003e\n\u003cli\u003eGoal: biosimilar launches 2026–2027\u003c\/li\u003e\n\u003cli\u003eModel: API-to-finished dose integration\u003c\/li\u003e\n\u003cli\u003eMarket: \u0026gt;US$60bn global insulin by 2030\u003c\/li\u003e\n\u003cli\u003eRegulatory: FDA\/EMA biosimilar pathways, interchangeability work ongoing\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpbeyond its own branded and generic products amphastar pharmaceuticals offers contract manufacturing services from u.s. mexico india facilities leveraging injectable inhalation expertise to serve other pharma companies.\u003e\u003cpthese services use high-tech suites and fda quality systems contributed about of revenue total help spread fixed costs across more production runs.\u003e\u003cpthey diversify revenue and improve asset utilization lowering per-unit cost shortening idle time for capital-intensive equipment.\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024: contract mfg ≈ $68M (12% of revenue)\u003c\/li\u003e\n\u003cli\u003eFacilities: U.S., Mexico, India; injectables + inhalation\u003c\/li\u003e\n\u003cli\u003eCompliance: FDA\/EMA standards; high-tech suites\u003c\/li\u003e\n\u003cli\u003eBenefit: diversifies revenue; raises asset utilization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthey\u003e\u003c\/pthese\u003e\u003c\/pbeyond\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmphastar: Primatene-led OTC, $220M injectables, contract manufacturing \u0026amp; insulin biosimilars\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmphastar’s product mix centers on Primatene Mist (≈65% OTC asthma share, $145M revenue 2024), critical-care injectables ($220M injectables 2024), specialty generics (30–60% lower pricing), insulin biosimilars targeting 2026–27, and contract manufacturing (~$68M, 12% of 2024 revenue).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 Rev\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimatene Mist\u003c\/td\u003e\n\u003ctd\u003e$145M\u003c\/td\u003e\n\u003ctd\u003e65% OTC share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectables\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003ctd\u003eHospitals\/EMS\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract Mfg\u003c\/td\u003e\n\u003ctd\u003e$68M\u003c\/td\u003e\n\u003ctd\u003e12% rev\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Amphastar Pharmaceuticals’ Product, Price, Place, and Promotion strategies, using real brand practices and competitive context to ground the analysis for managers, consultants, and marketers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Amphastar Pharmaceuticals’ 4P marketing mix into a concise, leadership-ready snapshot highlighting product positioning, pricing strategy, distribution channels, and promotional tactics to accelerate adoption of its pain-relief portfolio.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMajor Pharmaceutical Wholesalers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmphastar distributes most products through McKesson, AmerisourceBergen, and Cardinal Health, which together handled over 70% of U.S. pharmaceutical wholesale volume in 2024; this ties Amphastar into a network serving ~60,000 retail pharmacies and 6,000 hospitals. By using these logistics leaders, Amphastar reports lower distribution SG\u0026amp;A per unit and leverages nationwide cold-chain and last-mile capacity to cover all 50 states efficiently. In 2024 Amphastar’s channel sales via the big three accounted for roughly 82% of its revenue, cutting capital spending on distribution assets and improving operating margin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Clinical Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpa significant portion of amphastar pharmaceuticals injectable portfolio is placed directly into hospital systems and specialized clinics with roughly its revenues tied to inpatient channels sales are often routed through group purchasing organizations that aggregate procurement for over u.s. hospitals. this placement helps ensure epinephrine other critical-care drugs stocked in ers icus supporting time-sensitive patient needs steady institutional demand.\u003e\n\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRetail Pharmacy and OTC Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmphastar places OTC Primatene Mist in national pharmacy chains (CVS, Walgreens), grocery stores, and big-box retailers (Walmart, Target), reaching an estimated 85%+ of US pharmacy shoppers as of 2025.\u003c\/p\u003e\n\u003cp\u003eThis broad placement makes nonprescription asthma relief widely accessible and supports impulse and repeat buys without a prescription.\u003c\/p\u003e\n\u003cp\u003eMaintaining high shelf visibility and planogram placement—often via paid shelf space and 12–16% in-store promotional displays—drives awareness and convenience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpamphastar has expanded its global footprint with distribution and manufacturing hubs in china the united kingdom enabling faster regulatory approvals local supply-chain control accounted for of pharma spending growth uk remains a gateway to eu networks.\u003e\n\u003cpthese hubs reduce lead times and logistics costs reported a decrease in international delivery position amphastar to enter emerging markets where healthcare spending rose cagr\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHubs: China, United Kingdom\u003c\/li\u003e\n\u003cli\u003e2023: 12% shorter delivery times\u003c\/li\u003e\n\u003cli\u003eChina: 18% of 2024 pharma spending growth\u003c\/li\u003e\n\u003cli\u003eEmerging markets healthcare spend: 6.1% CAGR (2020–2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthese\u003e\u003c\/pamphastar\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Government and Agency Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmphastar sells directly to federal and local agencies, including the Department of Veterans Affairs and emergency response departments, via contracts for bulk critical-care meds and generic injectables.\u003c\/p\u003e\n\u003cp\u003eThese government contracts—about 18% of Amphastar’s 2024 revenue, per company filings—provide predictable volume for high-turnover SKUs and lower revenue volatility.\u003c\/p\u003e\n\u003cp\u003eThey support emergency-prep stockpiles and public-health programs, often multi-year and price-volume based, stabilizing production planning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~18% of 2024 revenue from gov\/agency sales\u003c\/li\u003e\n\u003cli\u003eMulti-year contracts reduce volatility\u003c\/li\u003e\n\u003cli\u003eCovers critical-care injectables and emergency stockpiles\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmphastar: 82% sales via Big-3, 60% hospital injectables, Primatene 85%+ reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmphastar uses McKesson, AmerisourceBergen, Cardinal Health for 82% of 2024 revenue, serving ~60,000 pharmacies and 6,000 hospitals; 60% of injectable revenue via hospitals\/GPOs; OTC Primatene Mist reaches 85%+ of US pharmacy shoppers; gov\/agency contracts ~18% of 2024 revenue. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eBig-3 channel share (2024)\u003c\/td\u003e\n\u003ctd\u003e82%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacies served\u003c\/td\u003e\n\u003ctd\u003e~60,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals served\u003c\/td\u003e\n\u003ctd\u003e~6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInjectable revenue via hospitals\u003c\/td\u003e\n\u003ctd\u003e60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrimatene Mist reach (2025)\u003c\/td\u003e\n\u003ctd\u003e85%+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGov\/agency revenue (2024)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eAmphastar Pharmaceuticals 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Amphastar Pharmaceuticals 4P's Marketing Mix Analysis you’ll receive instantly after purchase—fully complete and ready to use with no surprises.\u003c\/p\u003e\n\u003cp\u003eThis is the exact, high-quality document included in your download; editable, comprehensive, and identical to the file available after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751117566329,"sku":"amphastar-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/amphastar-marketing-mix.png?v=1772227919","url":"https:\/\/growthsharematrix.com\/products\/amphastar-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}